01530nas a2200241   4500000000100000000000100001008004100002260001500043100001900058700001700077700002700094700001800121700001600139700001600155700002000171700002100191245011200212856004700324300000800371490000700379520088800386022001401274       2024                            d  c2024-04-291 aB. Yetkin-Arik1 aS. A. Jansen1 aS. Varderidou-Minasian1 aB. Westendorp1 aK.-P. Skarp1 aM. Altelaar1 aC. A. Lindemans1 aM. J. Lorenowicz00aMesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage  uhttps://doi.org/10.1186/s13287-024-03738-9  a1250 v153 aAllogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for leukemia and a range of non-malignant disorders. The success of the therapy is hampered by occurrence of acute graft-versus-host disease (aGvHD); an inflammatory response damaging recipient organs, with gut, liver, and skin being the most susceptible. Intestinal GvHD injury is often a life-threatening complication in patients unresponsive to steroid treatment. Allogeneic mesenchymal stromal/stem cell (MSC) infusions are a promising potential treatment for steroid-resistant aGvHD. Data from our institution and others demonstrate rescue of approximately 40–50% of aGvHD patients with MSCs in Phase I, II studies and minor side effects. Although promising, better understanding of MSC mode of action and patient response to MSC-based therapy is essential to improve this lifesaving treatment.  a1757-6512